906559-60-2

Usage

Uses

Used in Organic Synthesis:
(2S,5R)-2-ETHYL-5-METHYL-N-BOC-PIPERAZINE is utilized as a building block in organic synthesis for the creation of various molecules. Its unique structure and functional groups make it a valuable component in the synthesis of complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (2S,5R)-2-ETHYL-5-METHYL-N-BOC-PIPERAZINE serves as a key building block for the development of drug candidates. Its specific stereochemistry and functional groups allow for the design and synthesis of novel therapeutic agents with potential medicinal properties.
Used as a Precursor for Piperazine-Containing Molecules:
(2S,5R)-2-ETHYL-5-METHYL-N-BOC-PIPERAZINE is also employed as a precursor in the synthesis of diverse molecules that contain a piperazine moiety. Its presence in these molecules can contribute to their biological activity and potential applications in various fields, including medicine and chemistry.

InChI:InChI=1/C12H24N2O2/c1-6-10-7-13-9(2)8-14(10)11(15)16-12(3,4)5/h9-10,13H,6-8H2,1-5H3/t9-,10+/m1/s1

Upstream product

• 906810-51-3 (2S,5R)-1-tert-butoxycarbonyl-2-ethyl-5-methylpiperazine acetate 

Downstream Products

• 907208-00-8 C₂₆H₃₄ClN₅O₃ 

Relevant academic research and scientific papers

HETEROARYL SUBSTITUTED PYRAZINYL-PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having th